Stock Forecast

  Amarin Corporation plc ( AMRN) Stock. Should you Buy or Sell?    $ 1.37

0.02 (1.44 %)

Amarin Corporation plc Analysis

Updated on 10-09-2022
Symbol AMRN
Price $1.37
Beta 1.853
Volume Avg. $3.69 M
Market Cap $552.39 M
52 Week Range $1.09 - $5.52

Amarin Corporation plc opened the day at $1.37 which is +'1.44 % on yesterday's close. Amarin Corporation plc has a 52 week high of $5.52 and 52 week low of $1.09, which is a difference of $4.43. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $552.39 M and total net profit is $583187000 which means the company is trading at 0.95 times profit to market capitalization. Theoretically, if you were to buy Amarin Corporation plc for $552.39 M, it would take 15 years to get your money back. Amarin Corporation plc are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Amarin Corporation plc Stock Forecast - Is Amarin Corporation plc a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreBuy
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value

PE Ratio -5.457
Dividend Yiel 0.000
Net Profit Margin -0.210

Valuing Amarin Corporation plc

Price Book Value Ratio 0.940 Price To Book Ratio 0.940
Price To Sales Ratio 1.147 Price Earnings Ratio -5.457

How liquid is Amarin Corporation plc

Current Ratio 1.989
Quick Ratio 1.264


Debt Ratio 0.404 Debt Equity Ratio 0.678
Long Term Debt To Capitalization 0.017 Total Debt To Capitalization 0.000

Latest news about Amarin Corporation plc

Amarin to Present at H.C. Wainwright's 24th Annual Global Investment Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Date : 30/08/2022

Why Amarin Stock Was Plunging This Week

Investors weren't happy with the company's decision to cease operations in a large country.

Date : 26/08/2022

7 F-Rated Growth Stocks to Sell Before Q4

It's probably high time to look at your portfolio and see which growth stocks to sell. It has been a disappointing year on Wall Street, to say the least.

Date : 25/08/2022

Are Ocugen or Amarin Good Penny Stocks to Buy?

This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.

Date : 24/08/2022

For Amarin, Something Wishful This Way Comes

Amarin has seen sales of its lone drug, Vascepa, plummet against generic competition. Famed activist investor Alex Denner has recently taken a sizeable stake in the company.

Date : 14/08/2022

About Amarin Corporation plc

CEO : Mr. John Thero
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Market

Description :

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

My Newsletter

Sign Up For Updates & Newsletters